Stay updated on Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.4.3 has been added and Revision: v3.4.2 has been removed from the history.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedA new site revision (v3.4.2) was added and a prior funding notice (v3.4.1) removed; these administrative changes do not affect the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check39 days agoChange DetectedA new government funding notice about the NIH Clinical Center operating status has been added. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.6%

- Check46 days agoChange DetectedShow glossary option and color-coding explanations have been added to the study history page, clarifying how additions (green) and deletions (red) are displayed. The revision label updated to v3.4.0 and the 'No FEAR Act data' wording was removed in favor of the current phrasing. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.7%

- Check60 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4; no changes to study data or major content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check82 days agoChange DetectedA new page revision 'Revision: v3.3.3' was added, and the 'HHS Vulnerability Disclosure' link along with the earlier 'Revision: v3.3.2' label were removed.SummaryDifference0.1%

Stay in the know with updates to Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Capmatinib & Spartalizumab vs Docetaxel in NSCLC Clinical Trial page.